Integrated Platform for Hit Identification ～Hit expansion in Post HTS～
Discovering effective compounds through high-throughput screening is tough due to …
Integrated Platform for Hit Identification ～Phenotypic Drug Discovery～
Axcelead has two strengths in phenotypic drug discovery.
The first is …
Discussions Begin on Collaborative Genomic Drug Discovery Support Using the IQVIA Genome Wide Study Platform
Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa, Kanagawa; …
Luncheon seminar at the 43rd Workshop of the Korean Society of Nonclinical Study
Join us for our luncheon seminar and visit …
Interview with Ikeura, President and CEO of Axcelead, a holding company, was published in “PHARMA JAPAN”. 『Axcelead to Expand Overseas Biz, Shoots for 130 Billion Yen Sales and 5,000-Plus Researchers』
As a global CRDMO (Contract Research, Development and …
Change of President & CEO
Kanagawa, Japan, April 13, 2023 — We announced …
Orizuru Therapeutics and Axcelead DDP Collaborate on Drug Discovery Support Services Regarding iPS Cells
Kyoto and Kanagawa, Japan, March 10, 2023 — …